Bacteriophages are nature's way of controlling overpopulation of bacteria. From food safety to therapeutics, we harness their precision to make the world better.
From farm to pharmacy, our phage-based products deliver targeted bacterial control without the drawbacks of traditional antimicrobials.
Phage products that eliminate harmful bacteria like Listeria, Salmonella, and E. coli in food production without altering taste or nutrition.
Precision probiotics and phage-based supplements targeting gut health and microbiome optimization for improved wellness.
Clinical-stage phage therapy programs for treating antibiotic-resistant bacterial infections where traditional treatments fail.
Intralytix, Inc. receives multimillion-dollar Research Program Project (P01) grant from the National Institutes of Health (NIH).
Read MoreIntralytix, Inc., a global leader in bacteriophage technology, has been awarded a Maryland Manufacturing 4.0 grant to enhance its phage manufacturing capabilities through the adoption of advanced Industry 4.0 technologies.
Read MoreIntralytix is excited to announce a new agreement with Life Extension to co-develop and commercialize a leading-edge phage-based nutraceutical aimed at expanding the role of bacteriophage technology within the vitamins, minerals, and supplements (VMS) sector.
Read MoreIntralytix, Inc., a global leader in bacteriophage technology, announced today that it has received formal approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA CVM) for its Salmonella-specific bacteriophage preparation for use as a processing aid to help control S. enterica in pet food and ingredients for use in pet food.
Read MoreIntralytix is using its core bacteriophage technology to develop novel natural products for use in food processing, environmental clean-up, sanitation, consumer products, and problems of antibiotic resistance in human therapy.
Pioneered the world’s first phage-based FDA clearance for food safety (ListShield™) in 2006. Secured extensive FDA & USDA regulatory approvals for EcoShield™, SalmoFresh™, and CampyShield™ across red meats, raw grains, produce, and pet foods.
Leading the development of targeted, clinical-stage human therapeutics. Secured FDA IND clearances to launch Phase 1/2a trials evaluating VRELysin™ (reducing gut VRE) and ShigActive™ (managing Shigella) in partnership with Johns Hopkins University and Mount Sinai.
Awarded competitive multimillion-dollar research grants and contracts from the National Institutes of Health (NIH), NIAID, and the USDA. Funding drives advanced pathogen research, including efforts targeting critical antimicrobial-resistant ESKAPE pathogens.
Driving innovation in biotech automation via AI and ML-driven manufacturing pipelines, pioneering scale-independent platforms for high-titer clinical phage preparations.
Partnering to expand phage applications globally. Key alliances in the (nutraceutical/VMS space), animal health (antibiotic alternatives in animal feed), and pharmaceutical spaces (Reproductive Medicine and Women's Health research).
Backed by robust scientific protection. Issued dozens of foundational patents by the USPTO and European Patent Office covering novel bacteriophages, formulations, and applications targeting MRSA, Shigella, and other critical pathogens.
Intralytix established to address growing problems in bacterial control.
Received world first phage-based FDA clearance for ListShield™ as a food additive.
Initiated early clinical trials for human therapeutic applications.
Expanded research & manufacturing facilities and therapeutic pipeline.
Access our latest publications, upcoming events, and valuable resources from across the phage community.
Elsevier • 2024
Microbiology Spectrum • 2024
Antibiotics • 2024
Sep 01 - 02, 2026
Oxford, UK
Mar 25 - 26, 2027
Sydney, Australia
Feb 18 - 19, 2027
Manila, Philippines
Intralytix's patent strategy provides broad and strong protection ranging from protecting specific bacteriophages that serve as the cornerstone of various Company products.
Learn how nature's oldest antibacterial agents are revolutionizing modern science and medicine.
Nature's most ubiquitous entity. Bad bacteria's natural, uncompromising enemy. We harness their precision for a safer world.
Bacteriophages, or phages, are viruses that naturally infect and kill bacteria. They are the most abundant biological entities on Earth and have co-evolved with bacteria for billions of years. Unlike antibiotics, phages are highly specific — each type targets only certain bacterial strains while leaving beneficial bacteria and human cells completely unharmed.
Yes. Phages are naturally present in our environment and our bodies. They cannot infect human cells — only bacteria. Our food safety products have GRAS (Generally Recognized as Safe) status from the FDA, and our therapeutic programs undergo rigorous clinical testing. Phages have been safely used in medicine for over 100 years.
Unlike broad-spectrum antibiotics that kill many types of bacteria (including beneficial ones), phages are precision tools that target only specific harmful bacteria. This preserves your microbiome, reduces side effects, and helps combat antibiotic resistance. Phages also naturally evolve, making bacterial resistance less likely to develop.
Phages have diverse applications: food safety (eliminating pathogens like Listeria and Salmonella), agriculture (protecting crops), human therapeutics (treating antibiotic-resistant infections), cosmetics (skin microbiome), and environmental remediation (cleaning contaminated sites).
Regulatory pathways vary by application. Our food safety products have achieved FDA GRAS status. Therapeutic phages are regulated as biological drugs and undergo clinical trials. We work closely with regulatory agencies worldwide to ensure our products meet the highest standards.
All Intralytix, Inc. products undergo rigorous safety testing and regulatory review. We work with leading regulatory agencies worldwide to ensure our products meet the highest standards.